BIOMARKERS & REGULATORY SCIENCE IN DILI
EARLY CAREER INVESTIGATORS FORUM. 6th CORE GROUP MEETING.
17-19 MARCH 2022. KAUNAS, LITHUANIA.
WORKING GROUPS/ 5th CORE GROUP/ 4th MANAGEMENT COMMITTEE MEETINGS / 3rd TRAINING SCHOOL. 11-13 OCTOBER 2021. NOTTINGHAM, UK
4th Core Group Meeting. COST Action 17112 PRO-EURO DILI NET. 26th November 2020. 2.00-3.00 PM (GMT)
CA-17112 Management Committee updates & Working Groups meeting @ EASL Digital International Liver Congress 2020
Lectures. 29th August 2020.
Core Group Meetings (CGM)
Management Committee Meetings (MCM)
Working Group Meetings (WGM)
Plenary lectures. 2 WGs Meeting. Palermo, 10th October 2019
Reports from WGs Leaders: where do we stand now? 2 WGs Meeting. Palermo, 10th October 2019
Short presentations from WGs Leaders. 1 WGs Meeting. Málaga, 14 March 2019
Plenary lectures. 1 WGs Meeting. Málaga, 14 March 2019
Lisbon, Portugal. October 19-21, 2021
2nd TRAINING COURSE, COST ACTION 17-112: RECENT ADVANCES ON STEM CELL RESEARCH AND CELL THERAPIES.
Lisbon, Portugal. 10th-11th October 2019
1st TRAINING COURSE, COST ACTION 17-112: ASSESSMENT OF DRUG-INDUCED LIVER INJURY: KEY RULES AND COMMON PITFALLS. HOW TO MAKE A CLINICAL NARRATIVE.
Recognition by EUROTOX as a Continuing professional development (CPD) course of 11 teaching hours.
Presentations
Grant beneficiaries & survey assessment
In order to support young investigator ́s career development and to encourage interactions among the participants in the COST Action 17112, we are launching a New Insights: Young Investigators Seminar Series. We propose this as a series of talks, ONCE monthly, given by early career investigators (ECIs) – with the supervision of their tutors (both hosts and mentors). The outline of the session would be a brief introduction of the speaker by the mentor, a talk around 45 min with 15 min left for discussion. Conferences will be held the 3rd Wednesday of each month at 16.30h (CET) starting from June 17.
Our next speaker will be Dr. Jorge Simón Espinosa, CIC bioGUNE , Metabolomics Unit, CIBERehd-ISCIII.
See the video here
Guest: Dr. Jorge Simón Espinosa
Date: 15th June 2022. 16.30h (CEST)
Our last speaker was Dr. Oleg Lunov, Ph.D. , he has completed a PhD in Molecular Medicine Ulm, Germany in 2011. After, he worked as post-doctoral researcher in the Institute of Pharmacology, Ulm University, Germany. In 2014 Dr. Lunov received Purkyně fellowship and joined Institute of Physics of the Czech Academy of Sciences, Prague. From 2016 Dr. Lunov is Head of the Laboratory of Biophysics at Institute of Physics of the Czech Academy of Sciences, Prague.
You can get more information in this web
See the video here Potential of nanoparticles as livery injury agents
Guest: Dr. Oleg Lunov, Ph.D.
Date: 18th May 2022. 16.30h (CEST)
Our last speaker was Daniel Di Zeo Sánchez, although now based in Malaga, Daniel’s family background comes from a long history of international mobility across 5 different countries. He graduated in Biochemistry with a mention in Molecular and Applied Biochemistry by the University of Malaga (UMA) and University of Seville (2013-2017) and holds a master’s in Advanced Biotechnology (UMA, 2018-2019). After finishing his superior studies, he benefited from long-term grants and contracts such as a 6-months grant for studying molecular biology of cancer, and an 18-month contract in the field of microbiology.
His most recent professional experience came at the end of 2019 when, moved for the curiosity of solving human health problems, he joined the Hepatogastroenterology, Pharmacology and Translational Clinical Therapeutics group at the Biomedical Research Institute of Malaga (IBIMA). Since then, he enrolled in the PhD programme of Biomedicine, Translational Research and New Health Technologies (UMA) to pursue his thesis project, focused on studying mechanistic and immunological features of the disease known as drug-induced liver injury, in continuous interaction with clinicians and the pharmaceutical industry.
Daniel di Zeo Sánchez will present his experience during a 3-month Short Term Scientific Mission in the laboratory of Prof. Joana P. Miranda, at the Faculty of Pharmacy of the University of Lisbon. During this period, he worked on in vitro techniques for the study of immunological mechanisms of drugs related to idiosyncratic hepatotoxicity, using different sources of liver and immune cells as models.
See the video here
Guest: Daniel Di Zeo Sánchez.
Our last speaker was be Prof. Dr. Jan G. Hengstler. Dr. Hengstler has completed a PhD in Medical and health sciences with a specialty of DNA damage at the University of MainzI. From 2007 Dr Hengstler is Professor (W3) and Scientific Director at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund.
See the video here:
Date: 16th March 2022, at 16.30h (CET)
Guest: Prof. Dr. Jan G. Hengstler.
Our last speaker was Pamela Bachour El Azzi, professor at the Lebanese University, Université Saint Joseph and Université Antonine for 7 years. She is commercial director and scientific consultant at Wepredic.
Dr. Bachour El Azzi has completed a PhD in Biology and health sciences with a specialty of toxicology at the Université de Rennes I and the Lebanese University. The main PhD work of Dr. Bachour El Azzi was the characterization of bile acid transporters in HepaRG cells and the investigation of drug-induced cholestatic mechanisms. She studied cellular mechanisms underlying chlorpromazine-induced intrahepatic cholestasis in vitro in the presence or not of an inflammatory context.
Drug-induced cholestasis: models, biomarkers and industrial challenges.
Date: 16th February 2022, at 16.30h (CET)
Guest: Pamela Bachour El Azzi
Our speaker was Ivan Capo from the University Clinical Centre of Vojvodina.
Role of histopathology in the assessment of animal models in DILI prediction.
Date: 21st January, at 16.30h (CET)
Guest: Ivan Capo
Our last speaker was Alejandro Hionides from the Oslo Universitetssykehus.
Generation of cell and gene iPSCs specific knockouts.
Date: 15th December, at 16.30h (CET)
Guest: Alejandro Hionides
Our last speaker was Lauryna Aukštikalnė, MD from the Lithuanian University of Health Sciences Hospital Kaunas Clinics.
Date: 20th October, at 16.30h (CEST)
Guest: Lauryna Aukštikalnė
Our next speaker was Goran Bokan, MD from the UCC RS of Banja Luka.
See the video here: Future perspectives in DILI-nisation: How to save the liver?
Date: 16th September, at 16.30h (CEST)
Guest: Goran Bokan
Our next speakers was Ismael Alvarez and Hao Niu from the Departments of Medicine and Pharmacology at Malaga University, IBIMA, who will be addressing an important topic on translational research in DILI
Clinical Trials and Drug-Induced Liver Injury: what have we learnt and where can we go.
As members of the working group on: Design and Endpoints in Clinical DILI Investigations and Trials, they have led a systematic review with meta-analysis on the treatment and prevention of DILI which may pave the way to set up an international multicentre research network to investigate the effectiveness of known and novel interventions that could improve clinical outcomes of DILI.
Date: 15th JULY, at 16.30h (CEST)
Guests: Ismael Alvarez, Hao Niu
Our first guest will be Nuria López-Alcántara who left Javier Cubero´s lab to enjoy a short term scientific-mission (STSM) in the laboratory of Oleg Lunov at the Institute of Physics in Prague (Czech Republic). She will narrate her experience and learning, will discuss the methods/ techniques used and what she aims to develop further in the future.
Date: 17th JUNE, at 16.30h (CET)
Guest: Nuria López-Alcántara
Short-Term Scientific Missions (STSMs). COST ACTION 17-112
- E-COST-GRANT-CA17112-966a467a
*Participant: Laura Moran, Universidad Complutense de Madrid (Madrid, Spain)
*Type of Mission: Clinical
*Location: Institute of Physics of the Czech Academy of Sciences (Prague, CZ)
*Responsible: Dr Oleg Lunov. Email: lunov@fzu.cz
*Dates: 2022-07-04 – 2022-09-30
- E-COST-GRANT-CA17112-24c11ac9.
*Participant: Olga Estévez Vázquez. Complutense University Madrid (Madrid, Spain)
*Type of Mission: Clinical
*Location: Bilkent University, Ankara (Turkey)
*Responsible: Dr Özlen Konu. Email: konu@fen.bilkent.edu.tr
*Dates: 2022-04-29 – 2022-07-24
- ECOST-STSM-Request-CA17112-48808. In vitro isolation of keratinocytes and fibroblasts from punch biopsy.
*Participant: Antonio Segovia Zafra, University of Málaga (Spain)
*Type of Mission: Clinical
*Location: National Reference Center for Rare Skin Diseases (Université
de Bordeaux), Bordeaux (France)
*Responsible: Dr Muriel Cario-André. Email: muriel.cario-andre@u-bordeaux.fr
*Dates: 2021-10-11 – 2021-10-24
- ECOST-STSM-Request-CA17112-48461. Establishment of iPSC differentiated to human hepatocyte knockouts.
*Participant: Alejandro Hionides. Universidad Complutense de Madrid (Madrid, Spain)
*Type of Mission: Clinical
*Location: University of Oslo, Sognsvannsveien 9, 0372 Oslo (Norway)
*Responsible: Dr Gareth John Sullivan. Email: g.j.sullivan@medisin.uio.no
*Dates: 2021-09-01 – 2021-10-31
- ECOST-STSM-Request-CA17112-48249. Advancing in vitro models of DILI: key techniques for the study of hepatotoxicity in cell cultures
*Participant: Daniel Enrique Di Zeo Sánchez. Biomedical Research Institute of Málaga (IBIMA) / University of Málaga (Málaga, Spain).
*Type of Mission: Clinical
*Location: Faculty of Pharmacy of the University of Lisbon
*Responsible: Joana Miranda. Email: jmiranda@ff.ul.pt
*Dates: 2021-07-01- 2021-07-31
- ECOST-STSM-Request-CA17112-48256
*Dates: 2021-09-01 – 2021-10-31
- ECOST-STSM-Request-CA17112-47460. DILI principles in detection, characterization, phenotyping, risk assessment and adjudication. Management of DILI databases. Pathophysiology, therapeutic strategies and new biomarkers in DILI using patient-derived dermal fibroblasts, keratinocytes and hep
*Participant: Lauryna Aukštikalnė. Lithuanian University of Health Sciences Institute of Physiology and Pharmacology (Kaunas)
*Type of Mission: Clinical
*Location: Universidad de Málaga (UMA), Málaga, Spain
*Responsible: Dr. María Isabel Lucena, lucena@uma.es
*Dates: 2021-01-11 – 2021-02-28
- ECOST-STSM-Request-CA17112-46009. Training in the use of HepaRGs and monitoring POR expression.
*Participant: Francisco Esteves. Faculdade de Ciências Médicas, UNL, Lisboa (Portugal).
*Type of Mission: Basic
*Location: Institute of Bioengineering, University of Edinburgh, Scotland (UK)
*Responsible: Dr. Leonard J. Nelson
*Dates: 01.03.2020-15.03.2020
- ECOST-STSM-Request-CA17112-46089. Methodology of systematic review of observational studies in DILI
*Participant: Cristiana Torres Freixo, Faculdade de Medicina. Universidade do Porto. Porto (Portugal)
*Type of Mission: Clinical
*Location: Nottingham Digestive Diseases Centre, Nottingham (UK)
*Responsible: Dr. Guruprasad Aithal
*Dates: 19.01.2020-05.02.2020
- ECOST-STSM-Request-CA17112-45167. ROLE OF NRF2 IN APAP-MEDIATED TOXICITY
*Participant: Nuria López-Alcántara (Spain)
*Type of Mission: Basic
*Location: Institute of Physics of the Czech Academy of Sciences, Prague (Czech Republic)
*Responsible: Dr. Oleg Lunov
*Dates: 02.12.2019-22.12.2019
- ECOST-STSM-Request-CA17112-45133. VIRAL AND AUTOIMMUNE HEPATITIS, CIRRHOSIS, ACUTE LIVER FAILURE, DILI, HILI INTRAHEPATIC CHOLESTASIS OF PREGNANCY
*Participant: Goran Bokan Faculty of medicine, Banja Luka, BA
*Type of Mission: Clinical
*Location: Internal Medicine & Hepatology, DIBIMIS, University of Palermo (Italy)
*Responsible: Dr. Anna Licata
*Dates: 30.09.2019-31.10.2019
- ECOST-STSM-Request-CA17112-45122. “SHORT TERM SCIENTIFIC MISSION” FOR THE LIVER FIBROSIS DIAGNOSIS THROUGH THE LIVER ELASTROGRAPHY.
*Participant: Enrique del Campo, UMA. Málaga (Spain)
*Type of Mission: Clinical
*Location: Internal Medicine & Hepatology, DIBIMIS, University of Palermo (Italy)
*Responsible: Dr. Anna Licata
*Dates: 10.07.2019-18.10.2019
Launch of Personalised Prescribing report
Prof Guruprasad Aithal, Vice Chair of the COST Action CA17112 who presented evidence to the working party said- ‘There are inter-individual variations in the way medicines work. Considering one’s genetic make-up assists while prescribing, increasing the benefits and reducing the adverse effect of the medications. We know of genetic variations which effect over 40 medicines. We are calling for Health Services to offer genetic tests to improve safe and effective prescribing’.
Co-branding rules are important in order to acknowledge COST as the funding source.
2ND PROGRESS REPORT (PR2) OF THE COST ACTION 17112
CA17112_PR2_ActionChairReport_2020-12-03
COST Action Progress Review at 24 months (16/10/2018 to 16/10/2020)
NEWSLETTERS
The Management Committee has approved the ITC conference grant awarded to the PhD Student, Ms. Joana Saraiva (Portugal) with the purpose of her attendance for the EUROTOX congress 2019 hold in Helsinki (8-11 September).
Her abstract entitled: “Hepatocyte-like cells in microfluidic devices: a new platform for disease modelling, drug screening and toxicology”
(Abstract ID: 250), submitted as “Poster” has been accepted and selected one of the 5 top posters presentation. She has adquired new concepts in pre-clinical methods in DILI that undoubtedly will help her to successfully continue her research on the field of DILI.